These are the posts from the How we think section that have been tagged with Patient.
To see all tags used in our posts, click here.
|25th January 2017
Simon Young, Director at Blue Latitude Health, discusses how advances in technology are influencing the future of the expert-patient relationship and why healthcare businesses must evaluate how best to support the future role of the expert.
|9th January 2017
In the 2017 trends edition of Perspective magazine, we explore how advances in technology are influencing the future of the expert-patient relationship and the role healthcare businesses can take in supporting and enhancing these interactions at the point of need.
|16th November 2016
Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for patients.
|2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
|3rd August 2016
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
|19th July 2016
In the last 13 years, only one new drug has been approved for patients with Alzheimer's Disease. The most recently approved drug was in 2014, bringing the total number of agents approved across AD to 5. In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as look at the some of the glimmers of light at the end of the tunnel.
|19th May 2016
Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
|30th March 2016
Healthcare is undergoing a transformative change, which presents challenges to all players in the sector. Established healthcare players like pharma need to control and shape their emerging roles.
In this article, Head of Insight Martine Leroy explores how pharma could learn from translational research organisations in adapting their approach to the changing healthcare landscape.
|15th September 2015
Traditionally, we look at the environment of the patient with the patient in the centre of a circle of healthcare professionals, carers, institutions or clinics, and sometimes services. Elisa del Galdo takes us through a better way to look at patient-centricity: with the patient’s journey at the centre.